Compare Carvana Co (CVNA) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Pfizer Inc — how do they compare? Carvana Co trades at $63.82 (market cap $69.55B), while Pfizer Inc trades at $27.83 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 2.3× Carvana Co's market cap, and Pfizer Inc pays a 6.18% dividend while Carvana Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and Pfizer Inc for 158 Days on average.
| CVNA | PFE | |
|---|---|---|
Market Cap | $69.55B | $158.56B |
Volume | 7,671,750 | 44,138,282 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $29.02 |
52-Week Low | $56.27 | $23.67 |
Typical Hold Time | 28 Days | 158 Days |
Enterprise Value | $72.04B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $62.76, down 1.72% on the day, amid a bearish technical signal despite strong fundamental performance. The company reported robust revenue growth, with 2025 revenue reaching $20.32B and net income of $1.41B, and has consistently beaten EPS estimates in recent quarters. Analyst consensus is mixed with a $84.07 price target, while technical indicators show resistance near $64 and support at $61.
Outlook remains cautiously optimistic given operational strength and growth trajectory, but high debt levels and competitive pressures pose risks. The stock offers upside if execution continues, yet volatility and macroeconomic factors warrant careful monitoring for investors.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
